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E 
ven by clinical and histologic findings alone it is reason- 
able to suspect that the pathogenesis of certain blistering 
skin diseases might involve abnormalities in adhesion struc- 
tures. The best defined buUous diseases in this regard are pem- 
phigus  (of which there are two basic types:  vulgaris and 
foliaceus) and bullous pemphigoid (BP) (1-3). Histology shows 
that the blisters in pemphigus result from a loss of cell-to- 
cell adhesion, a pathologic process called acantholysis. In pem- 
phigus vulgaris  (PV)  loss of adhesion occurs deep in the 
epidermis, just above the basal layer, whereas in pemphigus 
foliaceus (PF) the defective adhesion is more superficial,  in 
the granular layer. In BP blisters result from loss of adhesion 
of the basal  cells to the basement membrane. 
The next clue that adhesion structures might be involved 
in  these diseases  came when immunofluorescence studies 
demonstrated that both pemphigus and BP patients have au- 
toantibodies in their skin as well as in their serum (4).  In 
pemphigus  the autoantibodies were shown to be directed 
against the keratinocyte cell surface. In fact, investigators were 
so sure that these antibodies interfered directly with adhe- 
sion, they were termed, somewhat fancifully, anti-intercellular 
cement substance antibodies  (5).  In BP the antibodies are 
directed against the epidermal basement membrane zone. In 
both instances, the findings of autoantibodies in areas of defec- 
tive epidermal cell adhesion suggested that these antibodies 
might be directed against adhesion structures or molecules. 
The next stage in the evolution of our knowledge about 
these diseases  came when models were developed to  test 
whether patients' autoantibodies  are pathogenic. In pemphigus 
of both types the answer became dear: pemphigus IgG au- 
toantibodies  can  cause disease  (i.e.,  loss  of cell adhesion) 
without the additional contribution of complement or inflam- 
matory cells. This was shown by both a skin organ culture 
model (6) and passive transfer of autoantibodies to neonatal 
mice (7,8).  However, in BP the pathogenicity of the anti- 
bodies is not so clear-cut. Probably fixation of complement 
and recruitment of inflammatory cells is necessary for blister 
formation (9). Until recently, there has not been a good animal 
model to test this hypothesis. Now, however, it has been shown 
that rabbit antibodies raised to a major antigenic epitope of 
one of the BP antigens (defined below as BPAG2) can induce 
disease when passively  transferred to neonatal mice (10). 
From the above data, we know that pemphigus and BP 
are diseases with pathogenic autoantibodies directed against 
areas of the epidermis in which loss of cell-cell or cell-substrate 
adhesion occurs. Therefore, it was reasonable to hypothesize 
that these autoantibodies are directed against adhesion mole- 
cules or structures. This hypothesis has been confirmed (Table 
1). Immunochemical studies demonstrated that PF antigen 
is desmoglein 1 (Dsgl), a transmembrane glycoprotein of des- 
mosomes (11-13). Molecular cloning of Dsgl indicated that 
it is a member of the cadherin supergene family of calcium- 
dependent cell adhesion molecules (14).  Molecular cloning 
also revealed that PV antigen is a desmoglein (Dsg3) (14a). 
Both Dsgl  and Dsg3 have been localized by immunoelec- 
tron microscopy to desmosomes (15,  16) and, in keratino- 
cytes, both bind plakoglobin, a desmosomal plaque protein 
(17). Autoantibodies from PV patients, affinity purified on 
the extracellular region of Dsg3, cause blisters when passively 
transferred to neonatal mice, and the extracellular region of 
Dsg3 can completely absorb all pathogenic antibodies from 
PV sera (18,  19). 
Immunochemical studies indicated that BP autoantibodies 
actually identify two distinct proteins, now termed BPAG1 
and BPAG2.  BPAG1 was characterized by SDS-PAGE as an 
approximately 230-kD polypeptide, whereas BPAG2 was ap- 
proximately 180 kD (20, 21). Molecular cloning has confirmed 
that these two BP antigens are distinct gene products. BPAG1 
was found to be homologous in amino acid sequence and 
structure  to  desmoplakins  I/II,  alternatively  spliced  des- 
mosomal plaque proteins (22-24). Antibodies raised against 
BPAG1 have been localized by immunoelectron microscopy 
to the plaque of the hemidesmosome (25),  a ceil-basement 
membrane adhesion junction.  Therefore BPAG1  and des- 
moplakins I/II were the first members of a gene family of 
cell adhesion junction plaque proteins. Molecular cloning of 
BPAG2 indicated that it is a transmembrane protein with a 
COOH-terminal extracellular colhgenous domain, also local- 
ized by immunoelectron microscopy to the hemidesmosome 
(26-30). 
Once the antigens in the classical autoantibody-mediated 
blistering diseases were defined at a molecular level, it be- 
came clear that certain diseases defied easy classification,  and 
new diseases were thereby defined. One of these is paraneo- 
plastic pemphigus (31). This disease shares clinical and histo- 
logical features of PV and erythema multiforme (32). These 
patients have in vivo-bound antibodies against their epidermal 
basement membrane as well as cell surface, and they have serum 
antibodies that immunoprecipitate a distinct set of polypep- 
tides from epidermal extracts, dearly different from pemphigus 
antigens. Among these immunoprecipitated polypeptides are 
desmoplakins I/II as well as BPAG1, but the others are not 
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Disease  Autoantigen  Related molecules  Adhesion structure 








BP  BPAG1  Desmoplakins I/II  Hemidesmosome 
BPAG2  Collagens  Hemidesmosome 
Paraneoplastic pemphigus  Desmoplakins I/II,  BPAG1,  Desmoplakins I/II and  Desmosomes, 
others  BPAGI  are homologous  Hemidesmosomes 
Erythema multiforme,  major  Desmoplakins I/II  BPAG1  Desmosomes 
yet defined (33). Both desmoplakins I/II and BPAG1 are in- 
tracellular plaque proteins, as discussed above, and it is not 
clear that these are the crucial molecules involved in patho- 
genesis because it has not been shown that antibodies pene- 
trate living cells to cause pathology. 
In this issue of the The Journal of Experimental Medicine, 
Foedinger et al.  (34)  define another novel and potentially 
significant autoantibody in patients with erythema multiforme 
major. In this disease, patients do not exhibit defects in cell- 
to-cell adhesion, but they develop necrosis of the epidermis 
with dyskeratosis of keratinocytes. Blisters  develop because 
the necrotic epidermis detaches from the underlying dermis. 
These authors could detect antibodies against desmoplakins 
I/II in 6 of 6 patients with this disease. Antibodies were de- 
tected in epidermis by direct immunofluorescence of lesional 
skin, but not perilesional skin. Immunoblotting and immu- 
noprecipitation studies showed there were anti-desmoplakin 
I/II antibodies in the sera of these patients.  By direct and 
indirect immunoelectron microscopy, these antibodies bound 
the plaque of the desmosomes (i.e., the same location as des- 
moplakins I/II). When serum for these patients was injected 
subcutaneously, but not intraperitoneally, in neonatal mice 
these antibodies could be detected in keratinocytes by direct 
immunofluorescence. The authors speculate that when these 
antibodies enter the cell they might interfere with keratin 
filament binding to the desmosomal plaque and result in dys- 
keratosis (i.e.,  collapsed keratin filament networks). 
However, a key question remains regarding these newly 
defined autoantibodies: are they pathogenic? It is important 
to keep in mind that the authors only present a correlation 
between anti-desmoplakin  antibodies  and  erythema mul- 
tiforme major. The finding that, in one patient, these anti- 
bodies were seen during the first episode is not convincing 
evidence that  the antibodies  are pathogenic. Just  as with 
BPAG1 in BP and paraneoplastic pemphigus,  the question 
is whether autoantibodies reactive with in  tracellular compo- 
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nents of adhesion structures can enter living cells and cause 
pathology,  or is formation of these antibodies  an epiphe- 
nomenon? The fact that circulating anti-desmoplakin anti- 
bodies were only seen in erythema multiforme major, but 
not the less severe erythema multiforme minor (which can 
have identical skin lesions), suggests that they may be a re- 
sult (rather than cause) of disease, with more severe disease 
releasing more intracellular antigens which elicit an immune 
response. It seems unlikely that these antibodies enter un- 
damaged cells and cause disease. In the studies reported in 
this issue of the Journal, the antibodies entered keratinocytes 
when injected subcutaneously, but not intraperitoneally, in 
neonatal mice. This paradox could be explained if the locally 
injected serum caused inflammation and edema which damaged 
keratinocytes and permitted entry of antibodies. Of course, 
in erythema multiforme the hallmark of disease is necrotic 
keratinocytes which are presumably permeable to antibodies. 
In this respect, it is significant that only lesional skin of pa- 
tients had positive direct immunofluorescence  findings. Again, 
these findings suggest that only when they are damaged do 
the keratinocytes become permeable to these antibodies. These 
observations suggest that something other than the antibodies 
cause the initial damage to the keratinocyte. However, once 
that  damage occurs then  the anti-desmoplakin antibodies 
might play a role in amplification of the pathologic process. 
The future directions of research related to autoantibodies 
and blistering diseases will try to answer several of the ques- 
tions outlined above. Do these antibodies directly interfere 
with the function of adhesion molecules or is their effect more 
indirect, for example, through signal transduction? Can an- 
tibodies against cytoplasmic components of adhesion struc- 
tures cause disease or are these autoantibodies epiphenomena? 
Are there other anti-cell adhesion autoantibody diseases not 
yet defined? And, perhaps most importantly for the patients 
with these sometimes &wasting diseases, can we translate this 
basic  knowledge into new and effective therapies? Address correspondence to Dr. John R. Stanley, Dermatology Branch, National Institutes of Health, 
Bethesda, MD 20892. 
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